ESR1 and breast carcinoma: BELLE-3 was a randomized, double-blind, placebo-controlled, phase III study comparing Buparlisib plus fulvestrant to placebo plus fulvestrant in postmenopausal women with ER-Positive, HER2-negative advanced breast cancer progressing on or after mTOR inhibition [310].